Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Probiotics

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Microbiota Modulation by Antibiotics

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Bioreactor Controls-III

Bioreactor Controls-III

Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...

Prodrugs

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Serum Cytokine Profiles in Patients with Inflammatory Bowel Disease in Clinical Remission: A Cross-Sectional Comparison by Anti-TNF Therapy.

Journal of inflammation research·2026

Same author

Functional Shifts in Gut Microbiota and Associated Metabolites Suggest Gut-Brain Axis Dysregulation in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS).

Microorganisms·2026

Same author

Unbiased autoantibody screening using nucleic acid protein programmable array in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections.

Frontiers in behavioral neuroscience·2026

Same author

Excessive poly(ADP)-ribosylation in the inflamed mucosa of pediatric celiac disease points to a novel inflammatory mechanism and therapeutic target.

Molecular and cellular pediatrics·2026

Same author

Loss of Acid Ceramidase in Myeloid Cells Protects from Chronic Colitis in IL10-Deficent Mice.

bioRxiv : the preprint server for biology·2026

Same author

Isolation of In Vitro Osteoblastic-Derived Matrix Vesicles by Ultracentrifugation and Cell-Free Mineralization Assay.

Bio-protocol·2025

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Transformation of Probiotic Yeast and Their Recovery from Gastrointestinal Immune Tissues Following Oral Gavage in Mice

Transformation of Probiotic Yeast and Their Recovery from Gastrointestinal Immune Tissues Following Oral Gavage in Mice

Published on: February 8, 2016

From probiotics to therapeutics: another step forward?

Fayez K Ghishan¹, Pawel R Kiela

¹Department of Pediatrics, Steele Children's Research Center, University of Arizona Health Sciences Center, Tucson, Arizona 85724, USA. fghishan@peds.arizona.edu

The Journal of Clinical Investigation

|May 25, 2011

Summary

A novel probiotic factor, p40 from Lactobacillus rhamnosus GG, protects gastrointestinal cells via EGFR. This finding shows therapeutic potential for gut disorders, pending human trials.

More Related Videos

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods

Published on: September 10, 2016

Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation

Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation

Published on: October 31, 2019

Related Experiment Videos

Last Updated: Jun 1, 2026

Transformation of Probiotic Yeast and Their Recovery from Gastrointestinal Immune Tissues Following Oral Gavage in Mice

Transformation of Probiotic Yeast and Their Recovery from Gastrointestinal Immune Tissues Following Oral Gavage in Mice

Published on: February 8, 2016

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods

Published on: September 10, 2016

Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation

Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation

Published on: October 31, 2019

Area of Science:

Gastroenterology
Microbiology
Immunology

Background:

Probiotics show promise for gastrointestinal disorders by enhancing cytoprotection.
Clinical efficacy of probiotics remains inconsistent, necessitating further mechanistic studies.
Microbial products offer potential therapeutic avenues for gut diseases.

Purpose of the Study:

To elucidate a novel mechanism of cytoprotection mediated by a probiotic-derived factor.
To investigate the therapeutic potential of Lactobacillus rhamnosus GG's soluble product, p40, in gastrointestinal models.

Main Methods:

Investigated the role of p40, a soluble product of Lactobacillus rhamnosus GG.
Examined the mechanism of p40-mediated cytoprotection, focusing on epidermal growth factor receptor (EGFR) signaling.
Assessed the efficacy of p40 in preclinical models of chemically induced colitis.

Main Results:

Identified p40 as a key mediator of cytoprotection.
Demonstrated that p40's protective effects are dependent on EGFR signaling.
Showcased significant efficacy of p40 in ameliorating chemically induced colitis in preclinical models.

Conclusions:

p40 from Lactobacillus rhamnosus GG represents a novel therapeutic agent for gastrointestinal disorders.
EGFR-mediated signaling is a crucial pathway for probiotic-induced cytoprotection.
Further clinical validation is required to confirm p40's therapeutic potential in human patients.